

Remarks

The specification has been amended to add the "Cross Reference to related application" section showing that this application is claiming priority to an earlier US provisional application.

After entry of the above amendment, Claims 1-3, 9, 10, 14, 16, 17, 21, 26, 30, 31, 35, 40, 44, 45, 49, 54, 58, 59, 63, 68, 72 to 82, 84, 90, 91, 93, 94, 96, 97, 99, 104, 124 and 125 will be pending in this application.

Pending Claims 1-3, 72, 73, 74, 79, 81, 82 and 84 are original claims.

Pending Claims 9, 10, 14, 16, 17, 21, 26, 30, 31, 35, 40, 44, 45, 49, 54, 58, 59, 63, 68, 75 to 78, 80, 90, 91, 93, 94, 96, 97, 99 and 104 have been amended. Many of these pending claims were amended to merely remove dependencies of multiple dependent claims that dependent from another multiple dependent claim.

Claim 90 was amended to depend from 82 or 84 and "mammal" was amended to "individual"; support for this amendment can be found in original claim 89 and throughout the specification.

Claim 93 was amended to depend from 91 and "mammal" was amended to "individual"; support for this amendment can be found in original claim 92 and throughout the specification.

Claim 96 was amended to depend from 94 and "mammal" was amended to "individual"; support for this amendment can be found in original claim 95 and throughout the specification.

Claim 99 was amended to depend from 98 and "mammal" was amended to "individual"; support for this amendment can be found in original claim 98 and throughout the specification.

Claims 4 to 8, 11 to 13, 15, 18 to 20, 22 to 25, 27 to 29, 32 to 34, 36 to 39, 41 to 43, 46 to 48, 50 to 53, 55 to 57, 60 to 62, 64 to 67, 69 to 71, 83, 85 to 89, 92, 95, 98, 100 to 103 and 105 to 123 have been cancelled without prejudice.

New Claims 124 and 125 have been added without introducing new matter. Support for new claims can be found throughout the application and claims as originally filed. Support for new Claim 124 can be found from original claims. Additional support can be found in the specification, for example, for R_1 see published PCT application page 14, lines 3 to 13; for R_2 see page 14, line 15 to page 15, line 3; for R_3 see page 15 lines 4 to page 16 line 6; for R_4 see page 16, line 7 to page 17, line 11; for R_5 see page 17, line 12 to page 18, line 11, and for R_6 see page 18, line 12 to page 19, line 13. Support for new Claim 125 can be found throughout the specification, for example, page 1, lines 6 to 8, and also please see section entitled "Methods and Use" starting on page 23.


Appln. No.: PCT/US2004/019670
Preliminary Amendment Dated: December 16, 2005
Page 17 of 17

Docket No.: 66.US2.PCT

Applicants respectfully submitted that no new matter has been added by way of this amendment. The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16, 1.17, and 1.492 as required by this paper to Deposit Account No. 50-1441.

Respectfully submitted,

Date: December 16, 2005



Lyle W. Spruce, Ph.D.
Registration No. 53,631

Arena Pharmaceuticals, Inc.
6166 Nancy Ridge Drive
San Diego, CA 92121
Telephone: (858) 453-7200 x1425
Facsimile: (858) 677-0065